Study on the mechanism of Shenqi Dihuang Decoction in the treatment of IgA nephropathy by network pharmacology
LI Ming1 LI Liang1 LI Weinan2 BA Yuanming3
1.Department of Geriatric, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China;
2.Party Committee Office, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China;
3.Department of Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China
Abstract Objective To investigate the mechanism of Shenqi Dihuang Decoction in the treatment of IgA nephropathy by network pharmacology. Methods The effective active components of Shenqi Dihuang Decoction were obtained and their targets were predicted by using traditional Chinese medicine systems pharmacology database and analysis platform. At the same time, IgA nephropathy disease targets were screened by online Mendelian inheritance in man database, GWAS database, and GeneCards database, and drug targets and disease targets were mapped to obtain common targets. Proteinprotein interaction (PPI) networks were constructed from common targets and analyzed for GO and KEGG functional enrichment. Results In this study, 68 active components of Shenqi Dihuang Decoction were screened out, 200 potential targets were predicted, and 2038 targets of IgA nephropathy were screened out. Among them, 96 targets of Shenqi Dihuang Decoction were involved in IgA nephropathy. A 96-node, 1985-edge PPI network model was constructed, in which the key targets were MAPK1, CXCL8, Akt1, IL-6, JUN, TP53, VEGFA, TNF, MMP9, and PTGS2. GO enrichment analysis involved positive transcriptional regulation of RNA polymerase negative regulation of apoptotic process and hypoxia response. In addition, KEGG enrichment analysis results involved various pathogenic microbial infection signaling pathways and TNF signaling pathway. Conclusion Shenqi Dihuang Decoction has synergistic effects on IgA nephropathy through multiple components, multiple targets and multiple pathways, providing certain reference and support for the clinical application of Shenqi Dihuang Decoction.
LI Ming1 LI Liang1 LI Weinan2 BA Yuanming3. Study on the mechanism of Shenqi Dihuang Decoction in the treatment of IgA nephropathy by network pharmacology[J]. 中国医药导报, 2021, 18(29): 8-13.
[1] Rodrigues JC，Haas M，Reich HN. IgA Nephropathy [J]. Clin J Am Soc Nephrol，2017，12（4）：677-686.
[2] Woo KT，Foo MW，Choong HL，et al. IgA nephritic patients of Pacific Asian origin with increased risk of progression to end-stage renal disease [J]. Kidney Int，2014，86（3）：652-653.
[3] Floege J，Barbour SJ，Cattran DC，et al. Management and treatment of glomerular diseases（part 1）：conclusions from a Kidney Disease：Improving Global Outcomes（KDIGO）Controversies Conference [J]. Kidney Int，2019，95（2）：268-280.
[4] 范高伟，范军.国医大师张大宁治疗IgA肾病经验[J].湖南中医杂志，2019，35（3）：36-38.
[5] 林启展，马育鹏，潘碧琦，等.张琪教授辨治IgA肾病尿血证经验[J].广州中医药大学学报，2006（3）：234-236.
[6] 陈香美，陈以平，李平，等.1016例IgA肾病患者中医证候的多中心流行病学调查及相关因素分析[J].中国中西医结合杂志，2006（3）：197-201.
[7] Per?觢e M，Ve■eri■-Haler ?譕. The Role of IgA in the Pathogenesis of IgA Nephropathy [J]. Int J Mol Sci，2019，20（24）：6199.
[8] Chang S，Li XK. The Role of Immune Modulation in Pathogenesis of IgA Nephropathy [J]. Front Med （Lausanne），2020，7：92.
[9] 巴元明，林晓媛.邵朝弟治疗IgA肾病的经验[J].时珍国医国药，2015，26（3）：707-708.
[10] 李守然，温进，范婷.张根腾教授应用参芪地黄汤加减治疗慢性肾病的经验浅析[J].环球中医药，2014，7（10）：797-799.
[11] 郭彩慧.参芪地黄汤加减改善2型糖尿病患者早期肾病（气阴两虚型）临床疗效观察[D].成都：成都中医药大学，2016.
[12] 陈祥艳.参芪地黄汤治疗气阴两虚型IgA肾病的临床观察[D].杭州：浙江中医药大学，2013.
[13] 黄智莉.参芪地黄汤加减治疗IgA肾病30例[J].湖南中医杂志，2006，22（6）：42-43.
[14] 谢俊霞，周莉，杨恕.参芪地黄汤加减治疗IgA肾病的疗效观察[J].新医学导刊，2008，7（4）：134-135.
[15] Jin C，Miao X，Zhong Y，et al. The renoprotective effect of diosgenin on aristolochic acid I-induced renal injury in rats: impact on apoptosis, mitochondrial dynamics and autophagy [J]. Food Funct，2020，11（9）：7456-7467.
[16] Tamouza H，Chemouny JM，Raskova Kafkova L，et al. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy [J]. Kidney Int，2012，82（12）：1284-1296.
[17] Suh JS，Hahn WH，Cho BS. Polymorphisms of CXCL8 and its receptor CXCR2 contribute to the development and progression of childhood IgA nephropathy [J]. J Interferon Cytokine Res，2011，31（3）：309-315.
[18] Tian J，Wang Y，Guo H，et al. The Akt/mTOR/p70S6K pathway is activated in IgA nephropathy and rapamycin may represent a viable treatment option [J]. Exp Mol Pathol，2015，99（3）：435-440.
[19] 高原.肿瘤坏死因子α、白细胞介素6与IgA肾病足细胞损伤的相关研究[D].石家庄：河北医科大学，2017.
[20] Lopes TG，de Souza ML，da Silva VD，et al. Markers of renal fibrosis：How do they correlate with podocyte damage in glomerular diseases？[J]. PLoS One，2019，14（6）：e0217585.
[21] 于建军，师旭辉.IL-18、TNF-α、TGF-β1在IgA肾病中表达及其与病情进展的关系[J].辽宁医学杂志，2020， 34（4）：25-27.
[22] 魏晓岩，王彩丽.基质金属蛋白酶9及对肾脏疾病影响的研究进展[J].医学综述，2012，18（15）：2391-2393.
[23] 李晓蕾，金晓明，王天真，等.MIF和COX-2在实验性IgA肾病肾组织中的表达[J].齐齐哈尔医学院学报，2007，（10）：1164-1166.
[24] Couser WG，Johnson RJ. The etiology of glomerulonephritis：roles of infection and autoimmunity [J]. Kidney Int，2014，86（5）：905-914.
[25] Coppo R，Amore A，Peruzzi L，et al. Innate immunity and IgA Nephropathy [J]. J Nephrol，2010，23（6）：626-632.
[26] 赵成波，曾欢，王润秀，等.IgA肾病相关的免疫细胞膜分子及系膜细胞激活的研究进展[J].赣南医学院学报，2020，40（8）：848-852.
[27] Glassock RJ. The pathogenesis of IgA nephropathy [J]. Curr Opin Nephrol Hypertens，2011，20（2）：153-160.
